The treatment of tuberculosis in childhood
dc.contributor.author | Donald, Peter R. | |
dc.date.accessioned | 2010-12-21T13:53:25Z | |
dc.date.available | 2010-12-21T13:53:25Z | |
dc.date.issued | 2007-10 | |
dc.format.extent | 3 p. | |
dc.identifier.citation | Donald, PR 2007, 'The treatment of tuberculosis in childhood', South African Medical Journal, vol. 97, no. 10 , pp. 992-994. | en_ZA |
dc.identifier.issn | 0256-9574 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/5498 | |
dc.language.iso | en_US | en_ZA |
dc.publisher | SAMJ | en_ZA |
dc.subject | Amikacin | en_ZA |
dc.subject | Aminoglycoside antibiotic agent | en_ZA |
dc.subject | Aminosalicylic acid | en_ZA |
dc.subject | Antiretrovirus agent | en_ZA |
dc.subject | Capreomycin | en_ZA |
dc.subject | Carbamazepine | en_ZA |
dc.subject | Corticosteroid | en_ZA |
dc.subject | Cycloserine | en_ZA |
dc.subject | Digitalis | en_ZA |
dc.subject | Ethambutol | en_ZA |
dc.subject | Ethionamide | en_ZA |
dc.subject | Gatifloxacin | en_ZA |
dc.subject | Isoniazid | en_ZA |
dc.subject | Kanamycin | en_ZA |
dc.subject | Moxifloxacin | en_ZA |
dc.subject | Oral antidiabetic agent | en_ZA |
dc.subject | Phenytoin | en_ZA |
dc.subject | Protionamide | en_ZA |
dc.subject | Pyrazinamide | en_ZA |
dc.subject | Pyridoxine | en_ZA |
dc.subject | Quinoline derived antiinfective agent | en_ZA |
dc.subject | Rifampicin | en_ZA |
dc.subject | Streptomycin | en_ZA |
dc.subject | Terizidone | en_ZA |
dc.subject | Tuberculostatic agent | en_ZA |
dc.subject | Viomycin | en_ZA |
dc.subject | Acquired immune deficiency syndrome | en_ZA |
dc.subject | Antibacterial activity | en_ZA |
dc.subject | Arthralgia | en_ZA |
dc.subject | Arthritis | en_ZA |
dc.subject | Childhood disease | en_ZA |
dc.subject | Clinical protocol | en_ZA |
dc.subject | Color vision | en_ZA |
dc.subject | Drug blood level | en_ZA |
dc.subject | Drug hypersensitivity | en_ZA |
dc.subject | Drug response | en_ZA |
dc.subject | Exfoliative dermatitis | en_ZA |
dc.subject | Flu like syndrome | en_ZA |
dc.subject | Flushing | en_ZA |
dc.subject | Human immunodeficiency virus infection | en_ZA |
dc.subject | Hyperuricemia | en_ZA |
dc.subject | Liver toxicity | en_ZA |
dc.subject | Maximum permissible dose | en_ZA |
dc.subject | Multidrug resistance | en_ZA |
dc.subject | Mycobacterium | en_ZA |
dc.subject | Optic neuritis | en_ZA |
dc.subject | Perception deafness | en_ZA |
dc.subject | Peripheral neuropathy | en_ZA |
dc.subject | Psychosis | en_ZA |
dc.subject | Short course therapy | en_ZA |
dc.subject | Side effects | en_ZA |
dc.subject | Thrombocytopenia | en_ZA |
dc.subject | Tuberculosis | en_ZA |
dc.subject | Visual acuity | en_ZA |
dc.subject | Antitubercular agents | en_ZA |
dc.subject | Directly observed therapy | en_ZA |
dc.subject | Drug administration schedule | en_ZA |
dc.subject | Humans | en_ZA |
dc.subject | Tuberculosis in children -- Treatment | en |
dc.subject | Tuberculosis drugs | en |
dc.subject | Drug resistance | en |
dc.title | The treatment of tuberculosis in childhood | en_ZA |
dc.type | Article | en_ZA |